cobas® eplex bcid panels Search Results


cobas® eplex bcid panels  (GenMark Diagnostics)
90
GenMark Diagnostics cobas® eplex bcid panels
Cobas® Eplex Bcid Panels, supplied by GenMark Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cobas® eplex bcid panels/product/GenMark Diagnostics
Average 90 stars, based on 1 article reviews
cobas® eplex bcid panels - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
cobas ® eplex bcid-fp  (GenMark Diagnostics)
90
GenMark Diagnostics cobas ® eplex bcid-fp
Cobas ® Eplex Bcid Fp, supplied by GenMark Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cobas ® eplex bcid-fp/product/GenMark Diagnostics
Average 90 stars, based on 1 article reviews
cobas ® eplex bcid-fp - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
eplex bcid ruo panels  (BioFire Defense)
90
BioFire Defense eplex bcid ruo panels
Clinical isolates by final susceptibility phenotype profile among Gram-negative and Gram-positive organisms by treatment based on results of <t>ePlex</t> <t>BCID</t> panels versus Verigene BC. Comparison of theoretical antibiotic management decisions based on GenMark ePlex BCID <t>RUO</t> or Vergine BC results by final organism susceptibility profile. NA, no routine susceptibility testing (e.g., coagulase-negative Staphylococcus ) or uncommon profile (e.g., Stenotrophomonas maltophilia ).
Eplex Bcid Ruo Panels, supplied by BioFire Defense, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/eplex bcid ruo panels/product/BioFire Defense
Average 90 stars, based on 1 article reviews
eplex bcid ruo panels - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
filmarray blood culture id (bcid) panel  (BioFire Defense)
90
BioFire Defense filmarray blood culture id (bcid) panel
Comparison of RDT platforms
Filmarray Blood Culture Id (Bcid) Panel, supplied by BioFire Defense, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/filmarray blood culture id (bcid) panel/product/BioFire Defense
Average 90 stars, based on 1 article reviews
filmarray blood culture id (bcid) panel - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
dx eplex blood culture id (bcid  (GenMark Diagnostics)
90
GenMark Diagnostics dx eplex blood culture id (bcid
Clinical isolates by final susceptibility phenotype profile among Gram-negative and Gram-positive organisms by treatment based on results of <t>ePlex</t> <t>BCID</t> panels versus Verigene BC. Comparison of theoretical antibiotic management decisions based on GenMark ePlex BCID RUO or Vergine BC results by final organism susceptibility profile. NA, no routine susceptibility testing (e.g., coagulase-negative Staphylococcus ) or uncommon profile (e.g., Stenotrophomonas maltophilia ).
Dx Eplex Blood Culture Id (Bcid, supplied by GenMark Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dx eplex blood culture id (bcid/product/GenMark Diagnostics
Average 90 stars, based on 1 article reviews
dx eplex blood culture id (bcid - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
eplex blood culture identification gram-positive panel  (GenMark Diagnostics)
90
GenMark Diagnostics eplex blood culture identification gram-positive panel
Turnaround time and pathogen targets of FDA-cleared multiplex <t> blood culture identification </t> panels
Eplex Blood Culture Identification Gram Positive Panel, supplied by GenMark Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/eplex blood culture identification gram-positive panel/product/GenMark Diagnostics
Average 90 stars, based on 1 article reviews
eplex blood culture identification gram-positive panel - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
phenotest bc kit  (Accelerate Diagnostics)
90
Accelerate Diagnostics phenotest bc kit
Turnaround time and pathogen targets of FDA-cleared multiplex blood culture identification panels
Phenotest Bc Kit, supplied by Accelerate Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/phenotest bc kit/product/Accelerate Diagnostics
Average 90 stars, based on 1 article reviews
phenotest bc kit - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
eplex  (GenMark Diagnostics)
90
GenMark Diagnostics eplex
Turnaround time and pathogen targets of FDA-cleared multiplex blood culture identification panels
Eplex, supplied by GenMark Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/eplex/product/GenMark Diagnostics
Average 90 stars, based on 1 article reviews
eplex - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
eplex bcid-fp  (GenMark Diagnostics)
90
GenMark Diagnostics eplex bcid-fp
Turnaround time and pathogen targets of FDA-cleared multiplex blood culture identification panels
Eplex Bcid Fp, supplied by GenMark Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/eplex bcid-fp/product/GenMark Diagnostics
Average 90 stars, based on 1 article reviews
eplex bcid-fp - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
dx eplex bcid-gp panel cartridge  (GenMark Diagnostics)
90
GenMark Diagnostics dx eplex bcid-gp panel cartridge
Turnaround time and pathogen targets of FDA-cleared multiplex blood culture identification panels
Dx Eplex Bcid Gp Panel Cartridge, supplied by GenMark Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dx eplex bcid-gp panel cartridge/product/GenMark Diagnostics
Average 90 stars, based on 1 article reviews
dx eplex bcid-gp panel cartridge - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
biofire filmarray bcid2  (BioFire Defense)
90
BioFire Defense biofire filmarray bcid2
Turnaround time and pathogen targets of FDA-cleared multiplex blood culture identification panels
Biofire Filmarray Bcid2, supplied by BioFire Defense, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/biofire filmarray bcid2/product/BioFire Defense
Average 90 stars, based on 1 article reviews
biofire filmarray bcid2 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
eplex bcid  (GenMark Diagnostics)
90
GenMark Diagnostics eplex bcid
Clinical isolates by final susceptibility phenotype profile among Gram-negative and Gram-positive organisms by treatment based on results of <t>ePlex</t> <t>BCID</t> panels versus Verigene BC. Comparison of theoretical antibiotic management decisions based on GenMark ePlex BCID RUO or Vergine BC results by final organism susceptibility profile. NA, no routine susceptibility testing (e.g., coagulase-negative Staphylococcus ) or uncommon profile (e.g., Stenotrophomonas maltophilia ).
Eplex Bcid, supplied by GenMark Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/eplex bcid/product/GenMark Diagnostics
Average 90 stars, based on 1 article reviews
eplex bcid - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Clinical isolates by final susceptibility phenotype profile among Gram-negative and Gram-positive organisms by treatment based on results of ePlex BCID panels versus Verigene BC. Comparison of theoretical antibiotic management decisions based on GenMark ePlex BCID RUO or Vergine BC results by final organism susceptibility profile. NA, no routine susceptibility testing (e.g., coagulase-negative Staphylococcus ) or uncommon profile (e.g., Stenotrophomonas maltophilia ).

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Comparing the Clinical Utility of Rapid Diagnostics for Treatment of Bloodstream Infections Using Desirability of Outcome Ranking Approach for the Management of Antibiotic Therapy (DOOR-MAT)

doi: 10.1128/AAC.00441-21

Figure Lengend Snippet: Clinical isolates by final susceptibility phenotype profile among Gram-negative and Gram-positive organisms by treatment based on results of ePlex BCID panels versus Verigene BC. Comparison of theoretical antibiotic management decisions based on GenMark ePlex BCID RUO or Vergine BC results by final organism susceptibility profile. NA, no routine susceptibility testing (e.g., coagulase-negative Staphylococcus ) or uncommon profile (e.g., Stenotrophomonas maltophilia ).

Article Snippet: Recently, the ePlex BCID RUO panels were compared to the BioFire FilmArray blood culture ID (BCID) panel in 137 clinical blood cultures ( ).

Techniques: Comparison

Comparison of RDT platforms

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Comparing the Clinical Utility of Rapid Diagnostics for Treatment of Bloodstream Infections Using Desirability of Outcome Ranking Approach for the Management of Antibiotic Therapy (DOOR-MAT)

doi: 10.1128/AAC.00441-21

Figure Lengend Snippet: Comparison of RDT platforms

Article Snippet: Recently, the ePlex BCID RUO panels were compared to the BioFire FilmArray blood culture ID (BCID) panel in 137 clinical blood cultures ( ).

Techniques: Comparison, Bacteria

Comparison of RDT platforms

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Comparing the Clinical Utility of Rapid Diagnostics for Treatment of Bloodstream Infections Using Desirability of Outcome Ranking Approach for the Management of Antibiotic Therapy (DOOR-MAT)

doi: 10.1128/AAC.00441-21

Figure Lengend Snippet: Comparison of RDT platforms

Article Snippet: Recently, the ePlex BCID RUO panels were compared to the BioFire FilmArray blood culture ID (BCID) panel in 137 clinical blood cultures ( ).

Techniques:

Clinical isolates by final susceptibility phenotype profile among Gram-negative and Gram-positive organisms by treatment based on results of ePlex BCID panels versus Verigene BC. Comparison of theoretical antibiotic management decisions based on GenMark ePlex BCID RUO or Vergine BC results by final organism susceptibility profile. NA, no routine susceptibility testing (e.g., coagulase-negative Staphylococcus ) or uncommon profile (e.g., Stenotrophomonas maltophilia ).

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Comparing the Clinical Utility of Rapid Diagnostics for Treatment of Bloodstream Infections Using Desirability of Outcome Ranking Approach for the Management of Antibiotic Therapy (DOOR-MAT)

doi: 10.1128/AAC.00441-21

Figure Lengend Snippet: Clinical isolates by final susceptibility phenotype profile among Gram-negative and Gram-positive organisms by treatment based on results of ePlex BCID panels versus Verigene BC. Comparison of theoretical antibiotic management decisions based on GenMark ePlex BCID RUO or Vergine BC results by final organism susceptibility profile. NA, no routine susceptibility testing (e.g., coagulase-negative Staphylococcus ) or uncommon profile (e.g., Stenotrophomonas maltophilia ).

Article Snippet: An observational study was performed at University of Maryland Medical System comparing Verigene blood culture (BC) to GenMark Dx ePlex blood culture ID (BCID) (research use only) panels on blood cultures from adult patients.

Techniques:

Comparison of RDT platforms

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Comparing the Clinical Utility of Rapid Diagnostics for Treatment of Bloodstream Infections Using Desirability of Outcome Ranking Approach for the Management of Antibiotic Therapy (DOOR-MAT)

doi: 10.1128/AAC.00441-21

Figure Lengend Snippet: Comparison of RDT platforms

Article Snippet: An observational study was performed at University of Maryland Medical System comparing Verigene blood culture (BC) to GenMark Dx ePlex blood culture ID (BCID) (research use only) panels on blood cultures from adult patients.

Techniques:

Turnaround time and pathogen targets of FDA-cleared multiplex blood culture identification panels

Journal: Missouri Medicine

Article Title: Updates on Rapid Diagnostic Tests in Infectious Diseases

doi:

Figure Lengend Snippet: Turnaround time and pathogen targets of FDA-cleared multiplex blood culture identification panels

Article Snippet: There are currently four FDA-cleared molecular multiplex assays for blood culture pathogen identification: FilmArray BCID panel (bioMérieux, Marcy l’Etoile, France), Verigene Gram Positive Blood Culture ID assay (BCID-GP) and Gram Negative Blood Culture ID assay (BCID-GN) (Luminex Molecular Diagnostics, Toronto, Canada), Accelerate PhenoTest BC kit (Accelerate Diagnostics, Tucson, AZ), and ePlex Blood Culture Identification Gram-Positive Panel (BCID-GP) and Gram-Negative Panel (BCID-GN) (GenMark Diagnostics, Carlsbad, CA).

Techniques: Multiplex Assay, Bla VIM Assay

Turnaround time and pathogen targets of FDA-cleared multiplex blood culture identification panels

Journal: Missouri Medicine

Article Title: Updates on Rapid Diagnostic Tests in Infectious Diseases

doi:

Figure Lengend Snippet: Turnaround time and pathogen targets of FDA-cleared multiplex blood culture identification panels

Article Snippet: There are currently four FDA-cleared molecular multiplex assays for blood culture pathogen identification: FilmArray BCID panel (bioMérieux, Marcy l’Etoile, France), Verigene Gram Positive Blood Culture ID assay (BCID-GP) and Gram Negative Blood Culture ID assay (BCID-GN) (Luminex Molecular Diagnostics, Toronto, Canada), Accelerate PhenoTest BC kit (Accelerate Diagnostics, Tucson, AZ), and ePlex Blood Culture Identification Gram-Positive Panel (BCID-GP) and Gram-Negative Panel (BCID-GN) (GenMark Diagnostics, Carlsbad, CA).

Techniques: Multiplex Assay, Bla VIM Assay

Clinical isolates by final susceptibility phenotype profile among Gram-negative and Gram-positive organisms by treatment based on results of ePlex BCID panels versus Verigene BC. Comparison of theoretical antibiotic management decisions based on GenMark ePlex BCID RUO or Vergine BC results by final organism susceptibility profile. NA, no routine susceptibility testing (e.g., coagulase-negative Staphylococcus ) or uncommon profile (e.g., Stenotrophomonas maltophilia ).

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Comparing the Clinical Utility of Rapid Diagnostics for Treatment of Bloodstream Infections Using Desirability of Outcome Ranking Approach for the Management of Antibiotic Therapy (DOOR-MAT)

doi: 10.1128/AAC.00441-21

Figure Lengend Snippet: Clinical isolates by final susceptibility phenotype profile among Gram-negative and Gram-positive organisms by treatment based on results of ePlex BCID panels versus Verigene BC. Comparison of theoretical antibiotic management decisions based on GenMark ePlex BCID RUO or Vergine BC results by final organism susceptibility profile. NA, no routine susceptibility testing (e.g., coagulase-negative Staphylococcus ) or uncommon profile (e.g., Stenotrophomonas maltophilia ).

Article Snippet: In this study, the GenMark ePlex BCID had a higher mean DOOR-MAT score due to the expanded number of targets identified.

Techniques:

Comparison of RDT platforms

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Comparing the Clinical Utility of Rapid Diagnostics for Treatment of Bloodstream Infections Using Desirability of Outcome Ranking Approach for the Management of Antibiotic Therapy (DOOR-MAT)

doi: 10.1128/AAC.00441-21

Figure Lengend Snippet: Comparison of RDT platforms

Article Snippet: In this study, the GenMark ePlex BCID had a higher mean DOOR-MAT score due to the expanded number of targets identified.

Techniques: